Published in J Immunol on January 01, 1983
Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice. Infect Immun (1990) 1.44
Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev (1995) 1.32
Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells. Infect Immun (1990) 1.31
Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein. Infect Immun (1985) 1.21
Recurrent genital tract infection: a result of induced immunosuppression? Genitourin Med (1989) 1.09
Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin Exp Immunol (1999) 1.08
Immune suppression induced by Actinobacillus actinomycetemcomitans: effects on immunoglobulin production by human B cells. Infect Immun (1990) 1.04
Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. Infect Immun (1995) 0.95
Suppression of T-lymphocyte response by Coccidioides immitis antigen. Infect Immun (1988) 0.94
Role of bacterial lipopolysaccharide in enhancing host immune response to Candida albicans. Clin Dev Immunol (2013) 0.91
Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev (1995) 0.91
Induction of natural killer cell activity by inactivated Candida albicans in mice. Infect Immun (1985) 0.89
Immunological activities of a Candida albicans protein which plays an important role in the survival of the microorganism in the host. Infect Immun (1993) 0.85
Expression of the C3d-binding protein (CR2) from Candida albicans during experimental candidiasis as measured by lymphoblastogenesis. Infect Immun (1992) 0.84
Immunosuppressive effects of Centipeda periodontii: selective cytotoxicity for lymphocytes and monocytes. Infect Immun (1987) 0.82
A further characterization of Candida albicans-induced suppressor B-cell activity. Immunology (1989) 0.81
Immunoresponses to Neisseria meningitidis epitopes: primary versus secondary antiphosphorylcholine responses. Infect Immun (1985) 0.78
The role of thymus-dependent cell-mediated immunity in resistance to experimental disseminated candidiasis. J Reticuloendothel Soc (1976) 1.87
Opioids, opioid receptors, and the immune response. Drug Alcohol Depend (2001) 1.72
Immunity to Candida albicans. Microbiol Rev (1980) 1.66
Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol (2008) 1.23
Morphine induces sepsis in mice. J Infect Dis (1997) 1.19
The role of activated macrophages in resistance to experimental renal candidiasis. J Reticuloendothel Soc (1977) 1.07
Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther (1993) 1.04
Immunomodulatory activity of mu- and kappa-selective opioid agonists. Proc Natl Acad Sci U S A (1991) 1.04
Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci (1993) 1.02
Partial characterization of a prostaglandin-induced suppressor factor. Cell Immunol (1980) 1.00
Immunosuppression induced by staphylococcal enterotoxin B. Cell Immunol (1982) 1.00
Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol (2000) 1.00
Morphine enhances interleukin-12 and the production of other pro-inflammatory cytokines in mouse peritoneal macrophages. J Leukoc Biol (2000) 0.99
Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood (2000) 0.98
The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1. Blood (2001) 0.96
The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc Soc Exp Biol Med (1996) 0.96
Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors. Clin Immunol (2001) 0.95
Effect of systemic candidiasis on blastogenesis of lymphocytes from germfree and conventional rats. Infect Immun (1978) 0.94
Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol (1996) 0.93
Mouse strain differences in immunosuppression by opioids in vitro. J Pharmacol Exp Ther (1995) 0.93
Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol Immunotoxicol (1992) 0.93
Morphine increases susceptibility to oral Salmonella typhimurium infection. J Infect Dis (2000) 0.93
Suppression of lymphocyte blastogenesis by Candida albicans. Clin Immunol Immunopathol (1978) 0.92
Oral administration of formaldehyde-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga-toxigenic Escherichia coli. Infect Immun (2001) 0.92
Production and characterisation of monoclonal antibodies specific for staphylococcal enterotoxin B. J Med Microbiol (1988) 0.91
Expression of functional mu-opioid receptors during T cell development. J Neuroimmunol (2001) 0.91
Induction of suppressor cells by staphylococcal enterotoxin B: identification of a suppressor cell circuit in the generation of suppressor-effector cells. Immunology (1988) 0.90
Immunity to experimental renal candidiasis in rats. Infect Immun (1978) 0.89
Induction of suppressor cells in vitro by Candida albicans. Cell Immunol (1986) 0.88
Both T cells and macrophages are targets of kappa-opioid-induced immunosuppression. Brain Behav Immun (1994) 0.87
Immunosuppressive effects of morphine on immune responses in mice. Adv Exp Med Biol (1993) 0.87
Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). I. Analysis of the PITS beta factor. Cell Immunol (1982) 0.86
Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H. J Pharmacol Exp Ther (1995) 0.86
Direct activation of murine T cells by staphylococcal enterotoxins. Cell Immunol (1992) 0.86
Cytokine reversal of morphine-induced suppression of the antibody response. J Pharmacol Exp Ther (1993) 0.85
Effect of Friend leukemia virus infection on susceptibility to Candida albicans. Infect Immun (1990) 0.85
Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B. Immunology (1998) 0.84
Immunosuppressive activity of staphylococcal enterotoxin B. I. Characterization of staphylococcal enterotoxin-B-induced suppressor cells. Cell Immunol (1990) 0.84
Immunosuppressive properties of leukotriene D4 and E4 in vitro. Biochem Biophys Res Commun (1982) 0.84
Modulation of macrophage phagocytic activity by cell wall components of Candida albicans. Cell Immunol (1995) 0.84
Localisation of the mitogenic epitope of staphylococcal enterotoxin B. J Med Microbiol (1992) 0.83
Effect of 5''-methylthioadenosine and its analogs on murine lymphoid cell proliferation. Cancer Res (1981) 0.83
Interactions of opioid receptors, chemokines, and chemokine receptors. Adv Exp Med Biol (2001) 0.83
Suppression of cytolytic T-cell activity by staphylococcal enterotoxin B-induced suppressor cells: role of interleukin 2. Cell Immunol (1986) 0.83
Induction of immunosuppressive B-lymphocytes with components of Candida albicans. Adv Exp Med Biol (1988) 0.83
Crosstalk between chemokine and opioid receptors results in downmodulation of cell migration. Adv Exp Med Biol (2001) 0.83
Sequence of kappa-opioid receptor cDNA in the R1.1 thymoma cell line. J Neuroimmunol (1995) 0.83
Effect of isotypic and allotypic variations of MHC class II molecules on staphylococcal enterotoxin presentation to murine T cells. Cell Immunol (1992) 0.83
Morphine depresses macrophage numbers and function in mouse spleens. Adv Exp Med Biol (1998) 0.82
Opioids, receptors, and immunity. Adv Exp Med Biol (1993) 0.82
Mutations affecting the superantigen activity of staphylococcal enterotoxin B. Immunology (1997) 0.82
Endogenous prostaglandin synthesis and the control of lymphocyte function. Ann N Y Acad Sci (1979) 0.82
Effect of opioids on oral Salmonella infection and immune function. Adv Exp Med Biol (2001) 0.81
Inhibition of T cell superantigen responses following treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol (1997) 0.81
A further characterization of Candida albicans-induced suppressor B-cell activity. Immunology (1989) 0.81
Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages. J Neuroimmunol (1998) 0.81
The induction of T-suppressor cells with a soluble extract of Candida albicans. Cell Immunol (1989) 0.80
Characterization and genetic restriction of suppressor-effector cells induced by staphylococcal enterotoxin B. J Immunol (1990) 0.80
Immunomodulatory activity of staphylococcal enterotoxin-B. The induction of an I-J-restricted suppressor factor. J Immunol (1989) 0.80
Detection of kappa-opioid receptor mRNA in immature T cells. Adv Exp Med Biol (1995) 0.80
Dietary ascorbic acid and resistance to experimental renal candidiasis. J Nutr (1983) 0.79
Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses. Int Immunopharmacol (2001) 0.79
Cell-density-regulated chemotactic responsiveness of keratinocytes in vitro. J Invest Dermatol (2001) 0.79
The regulation of the immune response to polyvinylpyrollidone: antigen induced changes in prostaglandin and cyclic nucleotide levels. Arch Immunol Ther Exp (Warsz) (1980) 0.79
High-performance liquid chromatography of staphylococcal enterotoxin B. J Chromatogr (1983) 0.79
Kappa-opioid regulation of thymocyte IL-7 receptor and C-C chemokine receptor 2 expression. J Immunol (2000) 0.79
Inhibitors of prostaglandin synthesis block the induction of staphylococcal enterotoxin B-activated T-suppressor cells. Cell Immunol (1983) 0.79
Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). II. Resolution of multiple PITS beta factors. Cell Immunol (1984) 0.78
Alteration of early T cell development by opioid and superantigen stimulation. Adv Exp Med Biol (2001) 0.78
In vivo analysis of a superantigen-induced T cell suppressor factor. Cell Immunol (1996) 0.78
Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. Clin Exp Immunol (2014) 0.78
Reactions of keratinocytes to in vitro millimeter wave exposure. Bioelectromagnetics (2001) 0.78
Production of IL-6 and TNF-alpha by the macrophage-like cell line RAW 264.7 after treatment with a cell wall extract of Candida albicans. J Interferon Cytokine Res (1996) 0.78
Modulation of DPK cell function by the kappa opioid agonist U50,488H. Adv Exp Med Biol (1998) 0.77
Activation of murine resident peritoneal macrophages by a cell wall extract of Candida albicans. J Med Vet Mycol (1996) 0.77
Requirement for accessory cells in suppression of MOPC-315 IgA secretion by staphylococcal enterotoxin B-induced T-suppressor cells. Cell Immunol (1990) 0.77
Chemical identification of a prostaglandin-induced T suppressor (PITS). Lymphokine Res (1985) 0.77
Morphine alters macrophage and lymphocyte populations in the spleen and peritoneal cavity. J Neuroimmunol (1997) 0.77
Inhibition of the delayed-type hypersensitivity response by staphylococcal enterotoxin B-induced suppressor T cells. Cell Immunol (1991) 0.76
Role of interleukin-2 in superantigen-induced T-cell anergy. Immunology (1999) 0.76
The cellular basis for opioid-induced immunosuppression. Adv Exp Med Biol (1995) 0.76
Identification and characterization of lymphocyte hybridomas by electrophoresis of glucose-6-phosphate isomerase isozymes. Methods Enzymol (1983) 0.76
Effects of in vivo morphine treatment on antibody responses in C57BL/6 bgJ/bgJ (beige) mice. Life Sci (1993) 0.76
Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med (1990) 0.75
Low CD4/CD8 Ratio in Bronchus-Associated Lymphoid Tissue Is Associated with Lung Allograft Rejection. J Transplant (2012) 0.75
Mouse strain differences in in vivo and in vitro immunosuppressive effects of opioids. Adv Exp Med Biol (1995) 0.75
Effects of Wy-18,251 (3-p-chlorophenyl)thiazolo[3,2-a]benzimidazole- 2-acetic acid), levamisole and indomethacin on the generation of murine T suppressor cells in vitro. J Immunopharmacol (1985) 0.75
Penetrating radiography of imploding and stagnating beryllium liners on the Z accelerator. Phys Rev Lett (2012) 0.75
Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressors (PITS)--III. Production of PITS beta factors from T-cell hybridomas. Int J Immunopharmacol (1985) 0.75
Characterization of antigen-specific suppressor factors induced by staphylococcal enterotoxin B. Cell Immunol (1991) 0.75
Molecular and biochemical evidence for receptors for drugs of abuse on immune cells. NIDA Res Monogr (1996) 0.75
Ear cropping: a technique. Vet Med Small Anim Clin (1977) 0.75
The effect of morphine and DAGO on the proliferative response of murine splenocytes. Adv Exp Med Biol (1991) 0.75
In vitro metabolism and toxicity assessment of toxin T-514 (Peroxisomicine A1) of Karwinskia humboldtiana in microsomes and primary cultured hepatocytes. Toxicol In Vitro (2005) 0.75
A rapid and highly sensitive method of identifying lymphocyte hybridomas by electrophoresis of glucose-phosphate isomerase isozymes. Anal Biochem (1981) 0.75
Detection of prostaglandin induced antigen-stimulated changes in splenic AMP levels by immunofluorescence. Prostaglandins Med (1980) 0.75
Immunosuppressive activity of staphylococcal enterotoxin B. II. Activation of suppressor-effector cells by a staphylococcal enterotoxin B-induced suppressor factor. Cell Immunol (1990) 0.75
Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations. J Am Acad Dermatol (1990) 0.75